Aduro Biotech, Inc. (NASDAQ:ADRO) EVP Dirk G. Brockstedt sold 4,123 shares of Aduro Biotech stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $8.04, for a total transaction of $33,148.92. Following the transaction, the executive vice president now directly owns 77,841 shares of the company’s stock, valued at $625,841.64. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Shares of Aduro Biotech, Inc. (NASDAQ ADRO) traded up $0.10 during trading on Friday, reaching $7.95. 558,200 shares of the company’s stock traded hands, compared to its average volume of 400,737. Aduro Biotech, Inc. has a twelve month low of $6.01 and a twelve month high of $15.52.

Aduro Biotech (NASDAQ:ADRO) last announced its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.03). Aduro Biotech had a negative return on equity of 39.28% and a negative net margin of 548.92%. The company had revenue of $3.79 million during the quarter, compared to the consensus estimate of $4.04 million. During the same quarter in the prior year, the firm earned ($0.54) earnings per share. The business’s revenue was up .0% compared to the same quarter last year. sell-side analysts predict that Aduro Biotech, Inc. will post -1.28 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was originally published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/aduro-biotech-inc-adro-evp-sells-33148-92-in-stock/1695901.html.

Several hedge funds have recently made changes to their positions in ADRO. Bank of New York Mellon Corp grew its stake in shares of Aduro Biotech by 3.8% in the first quarter. Bank of New York Mellon Corp now owns 148,166 shares of the biotechnology company’s stock worth $1,593,000 after acquiring an additional 5,470 shares during the period. Parametric Portfolio Associates LLC grew its stake in shares of Aduro Biotech by 15.9% in the first quarter. Parametric Portfolio Associates LLC now owns 15,424 shares of the biotechnology company’s stock worth $166,000 after acquiring an additional 2,119 shares during the period. American International Group Inc. grew its stake in shares of Aduro Biotech by 7.1% in the first quarter. American International Group Inc. now owns 21,840 shares of the biotechnology company’s stock worth $235,000 after acquiring an additional 1,447 shares during the period. Vanguard Group Inc. grew its stake in shares of Aduro Biotech by 2.1% in the first quarter. Vanguard Group Inc. now owns 2,382,916 shares of the biotechnology company’s stock worth $25,617,000 after acquiring an additional 48,840 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of Aduro Biotech by 6.0% in the first quarter. Geode Capital Management LLC now owns 262,809 shares of the biotechnology company’s stock worth $2,825,000 after acquiring an additional 14,946 shares during the period. Hedge funds and other institutional investors own 34.01% of the company’s stock.

A number of brokerages recently issued reports on ADRO. HC Wainwright set a $18.00 price target on shares of Aduro Biotech and gave the company a “buy” rating in a research report on Wednesday, November 1st. BidaskClub cut shares of Aduro Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Zacks Investment Research cut shares of Aduro Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Canaccord Genuity set a $30.00 target price on shares of Aduro Biotech and gave the stock a “buy” rating in a report on Thursday, August 3rd. Finally, William Blair reaffirmed an “outperform” rating on shares of Aduro Biotech in a report on Monday, October 2nd. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $19.14.

Aduro Biotech Company Profile

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Insider Buying and Selling by Quarter for Aduro Biotech (NASDAQ:ADRO)

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.